Tamoxifen and raloxifene have been approved for the primary prevention of breast cancer in high-risk women, but are associated with an increased risk of serious side effects. Few studies have characterized risk-benefit profiles for chemoprevention among women who initiate tamoxifen or raloxifene outside of a clinical trial setting. Use of raloxifene and tamoxifen for chemoprevention was self-reported in 2014 to 2016 by participants in The Sister Study, a prospective cohort of women with a sister who had been diagnosed with breast cancer. After exclusions, 432 current raloxifene users and 96 current tamoxifen users were matched to 4,307 and 953 nonusers, respectively, on age and year of cohort enrollment. Conditional logistic regression was used to evaluate characteristics associated with chemoprevention use. Risk-benefit profiles were examined using published indices that assess the level of evidence (none, moderate, strong) that the benefits of chemoprevention outweigh the risk of serious side effects. Among current chemoprevention users, 44% of tamoxifen users and 5% of raloxifene users had no evidence of a net benefit. In analyses of factors associated with chemoprevention use, having strong evidence of benefit was a significant predictor of raloxifene use, but not of tamoxifen use. In our sample of women with a first-degree family history of breast cancer, raloxifene was more commonly used for breast cancer prevention than tamoxifen. Most raloxifene users, but <60% of tamoxifen users, were likely to benefit. Use of risk-benefit tables can help women and their healthcare providers make an informed decision about breast cancer chemoprevention.
©2019 American Association for Cancer Research.
Conflict of interest statement
Conflicts of interest: The authors declare no potential conflicts of interest.
Risk-benefit profiles of women using tamoxifen for chemoprevention.J Natl Cancer Inst. 2014 Dec 3;107(1):354. doi: 10.1093/jnci/dju354. Print 2015 Jan. J Natl Cancer Inst. 2014. PMID: 25475563 Free PMC article.
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.J Clin Oncol. 2011 Jun 10;29(17):2327-33. doi: 10.1200/JCO.2010.33.0258. Epub 2011 May 2. J Clin Oncol. 2011. PMID: 21537036 Free PMC article.
Breast Cancer Chemoprevention in an Integrated Health Care Setting.JCO Clin Cancer Inform. 2017 Nov;1:1-12. doi: 10.1200/CCI.16.00059. JCO Clin Cancer Inform. 2017. PMID: 30657366
Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.CMAJ. 2001 Jun 12;164(12):1681-90. CMAJ. 2001. PMID: 11450210 Free PMC article. Review.
Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.Ann Intern Med. 2002 Jul 2;137(1):59-69. doi: 10.7326/0003-4819-137-1-200207020-00017. Ann Intern Med. 2002. PMID: 12093250 Review.